Finding Expandable Induced Cardiovascular Progenitor Cells.
Finding Expandable Induced Cardiovascular Progenitor Cells.
复制标题
DOI：
10.1161/circresaha.116.308679
复制
发表时间：
2016-06-24
影响因子：
20.1
通讯作者：
Wu JC
中科院分区：
文献类型：
--
作者：
Chen IY;Wu JC
心血管祖细胞（CPC）是用于心脏再生治疗的有希望的细胞来源，这是由于它们具有自我更新和分化为有益于心肌修复的各种心血管细胞类型的能力：心肌细胞、平滑肌细胞和内皮细胞。由于缺乏一种有效的方案来维持和扩大CPC的长期文化，以前的评估主要集中在他们的能力，三系分化，而不是自我更新。在最近一期的《细胞干细胞》杂志上，两组研究人员独立地报道了他们成功地分离、维持和扩增了培养中的小鼠CPC，传代次数超过18至20次（扩增1010至1015倍），在细胞培养和心肌梗死小鼠模型中忠实地保留了祖细胞表型和三系限制性分化的能力。本评论将讨论这两项研究的独特发现，强调每种CPC衍生/扩展技术的优点和缺点，并提出加速其临床转化所需的其他步骤。
Cardiovascular progenitor cells (CPCs) are a promising cell source for cardiac regenerative therapy owing to their ability for self-renewal and differentiation into various cardiovascular cell types beneficial for myocardial repair: cardiomyocytes, smooth muscle cells, and endothelial cells. Previous evaluations of exogenously derived CPCs have focused mainly on their capacity for tri-lineage differentiation rather than self-renewal, owing to the lack of an effective protocol to maintain and expand CPCs long-term in culture. In a recent issue of Cell Stem Cell, two groups of investigators independently reported their success in isolating, maintaining, and expanding mouse CPCs in culture for greater than 18 to 20 passages (1010- to 1015-fold expansion), with faithful preservation of progenitor phenotype and ability for tri-lineage-restricted differentiation in both cell culture and mouse models of myocardial infarction. This Commentary will discuss the unique findings of these two studies, highlight the strengths and weaknesses of each CPC derivation/expansion technique, and propose additional steps necessary to accelerate their clinical translation.